Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on SUMMIT THERAPEUTICS PLC. We currently have 80 research reports from 1 professional analysts.
|15Mar17 11:00||GNW||Summit Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference|
|28Feb17 12:00||GNW||Summit Therapeutics Recognises Tenth Annual Rare Disease Day|
|23Feb17 12:15||GNW||Summit Therapeutics plc : Exercise of Warrants|
|02Feb17 12:00||GNW||Summit Therapeutics to Participate in February Investor Conferences|
|01Feb17 12:00||GNW||Summit Outline Phase 3 Programme for Novel CDI Antibiotic Ridinilazole|
|25Jan17 12:45||GNW||Summit Therapeutics plc : Holding(s) in Company|
|19Jan17 16:11||GNW||Summit Therapeutics plc : Exercise of Options|
Frequency of research reports
Research reports on
SUMMIT THERAPEUTICS PLC
SUMMIT THERAPEUTICS PLC
N+1 Singer - Morning Song 02-02-2017
02 Feb 17
Avon Rubber (AVON LN) Q1 in line with expectations | Clipper Logistics (CLG LN) Contract win supplements organic growth | IDOX (IDOX LN) Completion of 6PM acquisition | Summit Therapeutics (SUMM LN) Phase III ridinilazole programme anticipated to commence in H1 2018
N+1 Singer - Summit Therapeutics - Dr David Roblin appointed Chief Operating Officer and R&D President
19 Jan 17
The appointment of Dr David Roblin as Chief Operating Officer and President of R&D strengthens the group’s management team as it continues to progress with its two development programmes, utrophin modulation for Duchenne Muscular Dystrophy (DMD) and C. difficile infection. We are looking forward to initial 24-week muscle biopsy data from the ongoing PhaseOut DMD trial in Q2/Q3 2017. We are currently forecasting $2.6bn of ezutromid peak sales, supported by the broad utility of the programme across all patients with DMD and in combination with other agents. Ridinilazole (C. difficile) Phase III preparation is ongoing as Summit continues to explore options to support future development. We remain positive on the group’s future prospects and its significant market potential.
N+1 Singer - Morning Song 19-01-2017
19 Jan 17
Actual Experience (ACT LN) 2017 – a milestone year for revenue | Bagir Group (BAGR LN) Independent NED appointment to strengthen Board composition | Bioquell (BQE LN) Reassuring pre-close statement | Carador Income Fund (CIFU LN) Q4 dividend increased to 2.75c, 0.5c higher than forecast | FreeAgent (FREE LN) Contract with Royal Bank of Scotland | Halfords Group (HFD LN) Excellent Q3 update, special divi and confidence in FX mitigations | N Brown Group (BWNG LN) Robust peak trading with reversal of drag from older titles | NCC Group (NCC LN) Interims confirm underlying business sound | St Ives (SIV LN) Downgrade | Summit Therapeutics (SUMM LN) Dr David Roblin appointed Chief Operating Officer and R&D President | Wilmington Group (WIL LN) Acquisition – Further scaling of Healthcare
N+1 Singer - Morning Song 16-12-2016
16 Dec 16
Findel (FDL LN) Appointment of new chairman | Fulham Shore (FUL LN) Strong set of interims | IQE (IQE LN) Strong momentum continues | Realm Therapeutics (RLM LN) Board appointment affirms drug development strategy | Summit Therapeutics (SUMM LN) Q3: a period of significant developments with utrophin programme
N+1 Singer - Summit Therapeutics - Q3: a period of significant developments with utrophin programme
15 Dec 16
Q3 was a period in which Summit entered into a substantial deal with Sarepta Therapeutics for its utrophin modulation pipeline, including its lead DMD programme ezutromid, in Europe. Summit retains commercialisation rights in the US market where it will market the drug on its own, offering significant upside potential. Initial 24-week muscle biopsy data from the PhaseOut DMD trial remains on track to be reported Q2/Q3 2017. A placebo controlled trial is expected to start in H2 2017, assuming positive interim data from the PhaseOut DMD trial, with data available for potential regulatory filings in 2019. We are currently forecasting $2.6bn of ezutromid peak sales, supported by the broad utility of the programme across all patients with DMD and in combination with other agents. Ridinilazole (C. difficile) Phase III preparation is ongoing as Summit continues to explore options to support future development. We remain positive on the group’s future prospects and its significant market potential.
N+1 Singer - Summit Therapeutics - PhaseOut DMD trial underway in the US
16 Nov 16
The start of PhaseOut DMD in the US is in line with expectations, following regulatory clearance in April 2016. Patient enrolment is ongoing in the UK following the recruitment of the first patient in June 2016. Data from the trial will be released periodically with the first muscle biopsy data expected Q2/Q3 2017. We are currently forecasting $2.6bn of ezutromid peak sales, supported by the broad utility of the programme across all patients with DMD and in combination with other agents. We remain extremely positive on the group’s future prospects and its significant market potential.
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results
N+1 Singer - EKF Diagnostics - Final results & potential buy back
20 Mar 17
FY16 prelims are slightly ahead of our latest expectations, those having been increased materially over the course of H2’16 as the strength of the recovery in trading became apparent. In order to maximise shareholder value, the directors are currently examining a potential break up of the group. This would also involve a delisting from AIM. A buy back offer at 21.5p would therefore be made to those investors that wish to exit now rather than holding their shares for the two years plus it would likely take to achieve a potentially higher realisation value for the businesses.
Good results, but further restructuring complex for investors
20 Mar 17
EKF Diagnostics FY 2016 results are slightly ahead of expectations, with both higher revenue and better EBITDA. Management has also announced plans to split the company into two separate companies, Point of Care and Laboratory Diagnostics, with the prospect of a delisting to manage the process. The primary metric for valuation of the two businesses is different consequently we believe that the separation is likely to generate significant value. However, in anticipation of the volatility likely given the restructuring announced this morning, despite the strength of the results, we reduce our recommendation to HOLD and maintain our 21p target price.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017